Evidence map›Paper›PMID 28573468›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2017

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Hongshan Li, Jingyu Yu, Chao Liu, Jiang Liu, Sriram Subramaniam, Hong Zhao, Gideon M Blumenthal, David C Turner, Claire Li, Malidi Ahamadi and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Hongshan LiFood and Drug Administration, Silver Spring, MD, USA.
Jingyu YuFood and Drug Administration, Silver Spring, MD, USA.
Chao LiuFood and Drug Administration, Silver Spring, MD, USA.
Jiang LiuFood and Drug Administration, Silver Spring, MD, USA.
Sriram SubramaniamFood and Drug Administration, Silver Spring, MD, USA.
Hong ZhaoFood and Drug Administration, Silver Spring, MD, USA.
Gideon M BlumenthalFood and Drug Administration, Silver Spring, MD, USA.
David C TurnerMerck & Co., Inc., Kenilworth, NJ, USA.
Claire LiMerck & Co., Inc., Kenilworth, NJ, USA.
Malidi AhamadiMerck & Co., Inc., Kenilworth, NJ, USA.
Rik de GreefQuantitative Solutions, A Certara Company, Oss, The Netherlands.
Manash ChatterjeeMerck & Co., Inc., Kenilworth, NJ, USA.
Anna G KondicMerck & Co., Inc., Kenilworth, NJ, USA.
Julie A StoneMerck & Co., Inc., Kenilworth, NJ, USA.
Brian P BoothFood and Drug Administration, Silver Spring, MD, USA.
Patricia KeeganFood and Drug Administration, Silver Spring, MD, USA.
Atiqur RahmanFood and Drug Administration, Silver Spring, MD, USA.
Yaning WangFood and Drug Administration, Silver Spring, MD, USA. Yaning.Wang@fda.hhs.gov.
United States Food and Drug Administration · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USCenter for Drug Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab is a monoclonal antibody that targets the programmed death-1 receptor to induce immune-mediated clearance (CL) of tumor cells. Originally approved by the US Food and Drug Administration in 2014 for treating patients with unresectable or metastatic melanoma, pembrolizumab is now also used to treat patients with non-small-cell lung cancer, classical Hodgkin lymphoma, head and neck cancer, and urothelial cancer. This paper describes the recently identified feature of pembrolizumab pharmacokinetics, the time-dependent or time-varying CL. Overall results indicate that CL decreases over the treatment period of a typical patient in a pattern well described by a sigmoidal function of time with three parameters: the maximum proportion change in CL from baseline (approximately I

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials as TopicFemaleHumansMaleMelanomaMiddle AgedTime FactorsYoung AdultAntibodies, Monoclonal, HumanizedAntineoplastic AgentspembrolizumabBest overall responseImmunotherapyMonoclonal antibodyOncologyPD-1PembrolizumabTime dependent pharmacokineticsTime varying clearance

Identifiers

PMID28573468
OpenAlexW2620733650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.